Should You Buy SpaceX Stock In October?
Key PointsElon Musk's space industrial giant is growing at a rapid clip as it tries to dominate both the space and AI opportunities.
Nasdaq News
Vector Science Invests In Gary Payton's Scoreboard To Develop Peptide Products For Athletes
(RTTNews) - Vector Science and Therapeutics Corp. (PAIN.V), a medical technology company developing drug delivery technology and pharma-grade peptide manufacturing, has entered into a strategic relationship with Scoreboard Inc., a performance wellness company co-founded by NBA Ha
Tesla Delivered 486,532 Vehicles in Q3. Here's the Margin Math That Will Decide the Earnings Reaction.
Key PointsThe EV maker’s total deliveries saw a slight sequential improvement over Q2’s number.
The Best ETF to Buy and Hold for the Next 20 Years
Key PointsThe Vanguard Morningstar Growth ETF is an effective tool for investors seeking broad-based growth-stock exposure.
Finally, Ford Is Free of the Overhang That Caused It to Lose Billions
Key PointsFord has officially recovered from a supplier fire that drastically hindered the automaker's ability to get aluminum sheeting.
Asian Shares Retreat After Oil Price Spike
(RTTNews) - Asian stocks ended mostly lower on Thursday as technology stocks retreated on concerns over a surge in AI-related corporate debt.
Taiwan Semiconductor Manufacturing Could Have Big News on Oct. 15
Key PointsTSMC is the only chip foundry capable of producing the high-processing power chips its clients need at scale.
3 Chip Stocks Up Over 6,000% in a Decade: 2 to Buy Now and 1 to Avoid
Key PointsNvidia still has a huge opportunity ahead, having transformed itself into a complete AI infrastructure company.
Biohaven Licenses IgG Degrader Portfolio To Ono Pharma In Key Asian Markets
(RTTNews) - Biohaven Ltd. (BHVN) has entered into a strategic licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd. under which Ono will obtain exclusive rights to develop and commercialize Biohaven's MoDE pan-IgG degrader portfolio in Japan, South Korea, Taiwan
Fed Chair Kevin Warsh Fired Back at President Donald Trump's Interest Rate Critiques With a Blunt 9-Word Statement
Key PointsFed Chair Warsh and his Federal Open Market Committee (FOMC) colleagues initiated the fourth rate-hiking cycle of the 21st century on Sept. 16.
3 Dividend Stocks Down Between 23% and 30% to Buy Right Now and Hold for a Decade
Key PointsThe slowing housing market hurts the swimming pool industry, but Pool Corp. still has a healthy business model.
Should You Buy Stocks in October? History’s Answer is Strikingly Clear.
Key PointsThe S&P 500 is advancing in the double digits in 2026, but headwinds have multiplied.
If You Had Invested $10,000 in Apple Stock 10 Years Ago, Here's How Much You'd Have Today
Key PointsApple shareholders have profited from a trailing-10-year total return of 1,190%.
Prediction: The S&P 500 Will Hit 10,000 in 2027
Key PointsThe S&P 500 is trading at a historically low PEG ratio and entering a historically strong period for stocks.
Bayer Moves To Expand KERENDIA Into Chronic Kidney Disease Without Diabetes
(RTTNews) - Bayer (BYR.L) announced that the U.S. FDA has accepted the company's supplemental New Drug Application for KERENDIA, seeking approval to treat adults with chronic kidney disease (CKD) without diabetes.
Riot Platforms Shouldn't Be Worth More Than Cipher Digital
Key PointsCipher Digital has 3.3 more gigawatts in its portfolio than Riot Platforms.
Richardson Q1 Profit Surges, Sees Profitable Growth In FY27; But Stock Drops
(RTTNews) - Richardson Electronics Ltd. (RELL), an engineering solutions company, announced a significant increase in profit for the first quarter of fiscal 2027, supported by higher sales across all business units. Looking ahead, the company said it projects fiscal 2027 to be an
Propanc Reports Positive Preclinical Pancreatic Cancer Data For PRP; Phase 1b Planned In Q1 2027
(RTTNews) - Propanc Biopharma, Inc. (PPCB), a biopharmaceutical company, highlighted new preclinical data for its lead investigational candidate PRP in pancreatic ductal adenocarcinoma (PDAC) and compared that profile with a clinical standard recently established by Revolution Me
Prediction: The Number That Will Move Intel Stock in October Isn't Revenue
Key PointsIntel forecast an adjusted gross margin of around 42% for the third quarter, just over the second quarter's 41.8%.
Galderma Nemluvio Data Show Durable Skin And Itch Benefits Through 3 Years
(RTTNews) - Galderma (GALD), a dermatology-focused company, will present new long-term data for Nemluvio in patients with moderate-to-severe atopic dermatitis and prurigo nodularis at the 2026 Fall Clinical Dermatology Conference being held October 8-11 in Las Vegas, United State
This feed is responsible for generating the rss feed related to the topic latest article
Subscribe to Nasdaq News feed